What patents cover Zepzelca (lurbinectedin), and who holds them?
Zepzelca is the brand name for lurbinectedin. Patent coverage typically sits with the drug’s developer and sponsor companies, but the exact set of active patents depends on the country and whether you mean composition-of-matter, method-of-use, or formulation/specific-process patents. Patent listings also change over time as new applications publish and older patents expire.
To identify the specific patents, you need the jurisdiction (for example, US vs. EU/UK vs. Japan) and the patent family. Most practical “Zepzelca patent” searches rely on regulatory-linked patent databases in the relevant market.
How do I find the current “Zepzelca patent list” in the US?
In the US, the most direct way to see which patents are tied to a brand drug is through FDA’s Orange Book. The Orange Book lists patents submitted for a product and labels each as a kind of patent (for example, drug substance, drug product, or method of use), along with key details like patent numbers and expiration.
If you search “Zepzelca Orange Book,” you can pull the active and expiring patents for the specific listed drug product and compare across dosage forms/strengths.
How do patents work in Europe (does the EU have an Orange Book equivalent)?
Europe generally uses a different framework than the US Orange Book. Patent rights can include national patents and (in many cases) European patents, often through the European Patent Office system, plus supplementary protection certificates (SPCs) that can extend effective market exclusivity for certain medicines.
A practical “Zepzelca patents in Europe” workflow is usually:
1) identify the European patent family (assignees and priority),
2) check which countries grant it, and
3) check whether an SPC is granted for the relevant product/active ingredient.
When do Zepzelca patents expire?
Expiry dates depend on:
- the specific patent number (composition vs. method vs. formulation),
- the jurisdiction, and
- whether an SPC applies and how long it extends protection.
Because different patents in the same family can expire on different dates, “the Zepzelca patent expiration” is rarely a single date. The correct answer requires pulling the Orange Book (US) and/or the relevant patent/SPC records (EU/UK) for lurbinectedin.
Can generics or biosimilars enter before Zepzelca patent expiry?
For a small-molecule cancer drug like lurbinectedin (Zepzelca), generic small-molecule products are typically the relevant competitor category, not biosimilars. Generics generally require regulatory approval and are constrained by patent/SPC protections until those rights expire or are successfully challenged/cleared.
If a generic applicant uses the Hatch-Waxman pathway in the US, litigation or settlement can delay entry even if the generic is approved (approval timing and “launch” timing can differ).
Are there patent challenges or lawsuits involving Zepzelca?
Patent challenges are usually litigated in the US (for example, under Hatch-Waxman) or via opposition/appeal processes in Europe, depending on the patent type. Whether there are active challenges for Zepzelca depends on the current filing and the specific patent(s) being asserted.
To check this, you typically search:
- court dockets for the asserted patent numbers (US),
- EPO opposition status for the European patent family (Europe),
- and company press releases or regulatory updates.
What’s the fastest way to get an exact list of “Zepzelca patents” for a specific country?
If you tell me the market (US, UK, Germany, France, EU, Japan, etc.) and whether you want:
- “all listed patents” (US Orange Book approach), or
- “key patent family coverage” (composition/method plus SPC),
I can help you narrow the search terms and explain how to interpret the results you find.
Quick clarification so I can give you the right patent info
Which jurisdiction do you mean by “Zepzelca patents” (US Orange Book, EU/UK SPC/patents, or another country), and do you want expiration dates or just the patent numbers?